Posts tagged infusion
WB downgrades Arrowhead Pharma to MP

William Blair downgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “market perform” from “outperform” and slashed its price target to $2 from $12. The stock closed at $4.39 on Tuesday.

Read More
Mesoblast diabetic kidney disease data published

Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current issue of the peer-reviewed journal, EBioMedicine. 

The paper concluded that a single intravenous infusion of MPC-300-IV was well tolerated and had positive effects on renal function at the 12-week primary endpoint in the trial with adult patients with Type 2 diabetic nephropathy.

Read More